NDC product
SOLUTION · Boehringer Ingelheim Pharma GmbH and Co. KG
NDC 12714-217 · Boehringer Ingelheim Pharma GmbH and Co. KG
Key facts
| Product NDC | 12714-217 |
|---|---|
| Nonproprietary name | Risankizumbab |
| Substances | RISANKIZUMAB |
| Dosage form | SOLUTION |
| Labeler | Boehringer Ingelheim Pharma GmbH and Co. KG |
| Product type | DRUG FOR FURTHER PROCESSING |
| Marketing category | DRUG FOR FURTHER PROCESSING |
| Marketing start | Apr 23, 2019 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: